Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial
Kim A. Reiss(University of Pennsylvania), Robert H. Vonderheide(University of Pennsylvania), Thomas B. Karasic(Hospital of the University of Pennsylvania), Mark H. O’Hara(University of Pennsylvania), Mary Kate Gosselin(University of Pennsylvania), Rosemarie Mick(University of Pennsylvania), Charles Schneider(University of Pennsylvania), Ursina Teitelbaum(University of Pennsylvania), Susan M. Domchek(University City Science Center), Alyssa Donze(University of Pennsylvania), Ryan Massa(University of Pennsylvania), Rashmi Tondon(University of Pennsylvania), Chioma Onyiah(University of Pennsylvania)
Cited by 137
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
|Nature Medicine|2021|519